b'Widest immune coverageComprehensive profiling for clinical and translational researchBoth cell type and function are key in determining mechanisms behind immune potency and persistence, immune-related adverse events and immunosuppression. For this reason, CyTOF has been adopted for use in hundreds of clinical trials worldwide for immune monitoring and biomarker discovery studies across broad areas including immuno-oncology, infectious disease, autoimmune disease and neuroscience.The top cancer immunotherapies have leveraged unique biomarkers found by CyTOF technologyConventional panel in25 surface markers*spectral fluorescenceAdditional simultaneous+25 intracellular/functional markers*coverage on CyTOF systemMERCK | pembrolizumabBiomarker for identification of drugPredictive biomarker of survivaltargets in multiple myeloma trials in pembro Phase 1 trial Unique BMS | nivolumab NOVARTIS | CAR T predictive Predictive biomarker of response inPredictive biomarker ofbiomarkercombination nivo Phase 2 trial response in CAR TCyTOF simultaneously profiles 50-plus surface and functional markersin a single panel* Competitor 25-color immunoprofiling assay. Pharma companies listed are the firms that manufacture and/or market the therapies in the published studies. Top cancer immunotherapies by revenue in 2023.'